AllSight
Companies · APGE · Biological Products, (No Diagnostic Substances)

Apogee Therapeutics, Inc. (APGE)

Apogee Therapeutics, Inc. (APGE) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

Apogee Therapeutics, Inc. (APGE) stock — financials & valuation

Key numbers for Apogee Therapeutics, Inc. (APGE): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 36/100 — a percentile rank of Apogee Therapeutics, Inc.’s fundamentals against Manufacturing peers, weakest on growth. A quality ranking, not a price prediction.

Market cap$10.2B
EV / EBITDA-31.4×
Return on equity-24.6%
ROIC-30.2%
Debt / equity0.0×
Dividend yield0.0%

Is Apogee Therapeutics, Inc. overvalued? P/B looks overvalued vs its 5-year range.

Independent of the events above — derived from Apogee Therapeutics, Inc.’s own financial statements and shown as context, never as advice.

Sep 3, 2026$10.9B acquisition
Apogee Therapeutics completes AbbVie’s $10.9B buyout, ending public trading
Aug 11, 2026
Shareholders approve AbbVie deal; pay vote fails, but closing remains intact
Aug 10, 2026
Quarterly loss widens as Phase 3 path stays on track
Related companies in Biological Products, (No Diagnostic Substances)
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact